Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 3.73
KBIO's Cash to Debt is ranked higher than
78% of the 1159 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.17 vs. KBIO: 3.73 )
KBIO' s 10-Year Cash to Debt Range
Min: 2.07   Max: No Debt
Current: 3.73

Z-Score: -7.49
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -917950.00
KBIO's Operating margin (%) is ranked lower than
58% of the 1110 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9.84 vs. KBIO: -917950.00 )
KBIO' s 10-Year Operating margin (%) Range
Min: -92975   Max: -11.19
Current: -917950

-92975
-11.19
Net-margin (%) -949950.00
KBIO's Net-margin (%) is ranked lower than
58% of the 1110 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.50 vs. KBIO: -949950.00 )
KBIO' s 10-Year Net-margin (%) Range
Min: -95336.36   Max: -11.02
Current: -949950

-95336.36
-11.02
ROE (%) -90.04
KBIO's ROE (%) is ranked lower than
54% of the 1139 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.62 vs. KBIO: -90.04 )
KBIO' s 10-Year ROE (%) Range
Min: -89.25   Max: -89.25
Current: -90.04

ROA (%) -63.18
KBIO's ROA (%) is ranked lower than
55% of the 1170 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.52 vs. KBIO: -63.18 )
KBIO' s 10-Year ROA (%) Range
Min: -107.14   Max: -62.46
Current: -63.18

-107.14
-62.46
ROC (Joel Greenblatt) (%) -11671.33
KBIO's ROC (Joel Greenblatt) (%) is ranked lower than
56% of the 1165 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 15.08 vs. KBIO: -11671.33 )
KBIO' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -20419.13   Max: -10642.9
Current: -11671.33

-20419.13
-10642.9
» KBIO's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

KBIO Guru Trades in Q1 2014

Jean-Marie Eveillard 1,746,591 sh (+99.61%)
Jim Simons 29,238 sh (+57.78%)
PRIMECAP Management 4,691,475 sh (-0.18%)
» More
Q2 2014

KBIO Guru Trades in Q2 2014

Jim Simons 245,301 sh (+738.98%)
Jean-Marie Eveillard 1,746,591 sh (unchged)
PRIMECAP Management 4,475,700 sh (-4.60%)
» More
Q3 2014

KBIO Guru Trades in Q3 2014

PRIMECAP Management 4,475,700 sh (unchged)
Jean-Marie Eveillard 1,746,591 sh (unchged)
Jim Simons 126,866 sh (-48.28%)
» More
Q4 2014

KBIO Guru Trades in Q4 2014

Jim Simons 264,900 sh (+108.80%)
PRIMECAP Management 4,475,700 sh (unchged)
Jean-Marie Eveillard 1,746,591 sh (unchged)
Jean-Marie Eveillard 1,746,591 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with KBIO

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 0.67
KBIO's P/B is ranked higher than
96% of the 1281 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.24 vs. KBIO: 0.67 )
KBIO' s 10-Year P/B Range
Min: 0.26   Max: 3.67
Current: 0.67

0.26
3.67
EV-to-EBIT 0.36
KBIO's EV-to-EBIT is ranked higher than
100% of the 1281 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 46.13 vs. KBIO: 0.36 )
KBIO' s 10-Year EV-to-EBIT Range
Min: -2.4   Max: 0.8
Current: 0.36

-2.4
0.8
Current Ratio 2.34
KBIO's Current Ratio is ranked higher than
73% of the 1155 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.10 vs. KBIO: 2.34 )
KBIO' s 10-Year Current Ratio Range
Min: 2.29   Max: 6.83
Current: 2.34

2.29
6.83
Quick Ratio 2.34
KBIO's Quick Ratio is ranked higher than
79% of the 1155 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.60 vs. KBIO: 2.34 )
KBIO' s 10-Year Quick Ratio Range
Min: 2.29   Max: 6.83
Current: 2.34

2.29
6.83

Valuation & Return

vs
industry
vs
history
Price/Net Cash 0.73
KBIO's Price/Net Cash is ranked higher than
99% of the 1281 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.00 vs. KBIO: 0.73 )
KBIO' s 10-Year Price/Net Cash Range
Min: 2.48   Max: 2.54
Current: 0.73

2.48
2.54
Price/Net Current Asset Value 0.69
KBIO's Price/Net Current Asset Value is ranked higher than
99% of the 1281 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.00 vs. KBIO: 0.69 )
KBIO' s 10-Year Price/Net Current Asset Value Range
Min: 2.4   Max: 2.44
Current: 0.69

2.4
2.44
Price/Tangible Book 0.67
KBIO's Price/Tangible Book is ranked higher than
97% of the 1281 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.30 vs. KBIO: 0.67 )
KBIO' s 10-Year Price/Tangible Book Range
Min: 1.52   Max: 2.86
Current: 0.67

1.52
2.86
Earnings Yield (Greenblatt) 277.80
KBIO's Earnings Yield (Greenblatt) is ranked higher than
99% of the 1155 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.80 vs. KBIO: 277.80 )
KBIO' s 10-Year Earnings Yield (Greenblatt) Range
Min: 122.4   Max: 3217.3
Current: 277.8

122.4
3217.3

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare: » details
Traded in other countries:0KB.Germany,
KaloBios Pharmaceuticals Inc. was incorporated on March 15, 2000. On February 5, 2013 the Company closed its initial public offering. The Company is a biopharmaceutical company engaged on the development of monoclonal antibody therapeutics for diseases that burdens the society and to patients and their families. With Humaneered antibody technology, the Company produced a portfolio of patient-targeted, first-in-class, antibodies to treat serious medical conditions with a clinical focus on respiratory diseases and cancer. Humaneered antibodies have tested clinically in over 250 patients with no evidence of immunogenicity. The Company identifies and develops products that treat multiple indications through proof-of-concept studies. The Company has advanced three antibodies to the clinical development stage: KB001-A, for the treatment of Pa VAP; KB004, for hematologic malignancies; and KB003, for severe asthma. KB001-A, is a Humaneered, recombinant, PEGylated, anti-Pseudomonas PcrV high-affinity Fab antibody that is being developed for the prevention and treatment of infections by Pa, a gram negative bacteria that can cause pneumonia in mechanically ventilated patients and chronic respiratory infections in individuals with CF. KB004 is a Humaneered, monoclonal antibody in which the carbohydrate chains lack fucose, thereby enhancing the targeted cell-killing activity of the antibody. KB003 is a Humaneered, recombinant monoclonal antibody that targets and neutralizes human granulocyte macrophage colony-stimulating factor, or GM-CSF, with potential for use in inflammatory, autoimmune and other indications. Humaneered technology platform addresses issues of therapeutic antibody engineering and down-stream processing issues. The Humaneered technology is a method for converting antibodies into engineered human antibodies designed for therapeutic use, particularly for chronic conditions. The technology is designed to produce antibodies that have specificity and affinity for their target antigen, low propensity for aggregation, and a long-term stability. KB001-A, KB003, and KB004 are all Humaneered antibodies or antibody fragments. The Company currently has a collaboration with Sanofi for the development of KB001-A, and have licensed its Humaneered technology non-exclusively to Novartis and also in-licensed certain rights from, among others, UCSF and LICR. The Company owns 12 issued U.S. patents, with another issued U.S. patent owned jointly with a third party. It has an exclusive license to seven U.S. patents and owns 49 issued foreign patents. The Company's competitors include pharmaceutical companies, biotechnology companies, academic institutions, and other research organizations. The Company also competes with Valneva, MedImmune, Micromet along with Nycomed among others.
» More Articles for KBIO

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
KALOBIOS PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers,... Apr 24 2015
KaloBios Elects Ronald A. Martell to Board of Directors Apr 22 2015
KaloBios Elects Ronald A. Martell to Board of Directors Apr 22 2015
KaloBios to Present at the 14th Annual Needham Healthcare Conference Apr 06 2015
KaloBios to Present at the 14th Annual Needham Healthcare Conference Apr 06 2015
KALOBIOS PHARMACEUTICALS INC Financials Mar 24 2015
KaloBios Reports Fourth Quarter 2014 Financial Results Mar 16 2015
KALOBIOS PHARMACEUTICALS INC Files SEC form 10-K, Annual Report Mar 16 2015
KaloBios Reports Fourth Quarter 2014 Financial Results Mar 16 2015
KALOBIOS PHARMACEUTICALS INC Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a... Feb 23 2015
KaloBios Announces Upcoming Investor Conference Participation Feb 03 2015
KALOBIOS PHARMACEUTICALS INC Files SEC form 8-K, Costs Associated with Exit or Disposal Activities,... Feb 02 2015
KALOBIOS PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers Jan 21 2015
KaloBios Announces Retirement of David W. Pritchard, President and Chief Executive Officer Jan 08 2015
KALOBIOS PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers,... Jan 08 2015
KaloBios Announces Retirement of David W. Pritchard, President and Chief Executive Officer Jan 08 2015
KaloBios Reports Top-Line Data for Phase 2 Study of KB001-A to Treat Pseudomonas Aeruginosa Lung... Jan 06 2015
KALOBIOS PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers,... Dec 01 2014
KaloBios Elects Robert A. Baffi, BioMarin Senior Executive, to Board of Directors Dec 01 2014
Akorn (AKRX) Worth Watching: Stock Adds 6.4% in Session Nov 14 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK